11 financing amounted to more than 100 million, cancer early screening industry into the harvest period - 2020 final inventory

In 2020, the cancer early screening market ushered in a leap forward development, Nohui Health, Kang Liming Biology,far gene and many other enterprises single financing amount of more than 100 million, focusing on the layout of cancer early screening track of the pan-birth son, stone-burning medicine are successfully listed on NASDAQ, because Maina for $8 billion to buy Grail, the first genetic test cancer early screening three types of evidence was born ... These big events occur intensively in 2020, indicating that the cancer early screening circuit has become a hot spot in the industry, from the stage of technology research and development to the stage of product commercialization, enterprises entered the harvest period.
Arterial network combed, summarized the 2020 cancer early screening market investment and financing data, products, technology, business model and other core elements of changes, got the following information: 1, a large amount of capital into the cancer early screening track, 10 financing amount of more than 100 million, capital will gradually gather to head enterprises; Source of genetic testing cancer early screening listed enterprises; 3, the first genetic testing cancer early screening registration certificate was born, compliance will become the mainstream of the market, enterprises need to pay attention to product certification work; 4, large-scale forward-looking research increased, industry development further mature; 5, ctDNA is the current hot early screening markers, multi-group will play an important role in the cancer early screening scene; 6, the medical examination center is the current stage of cancer early screening products important sales channels, to pay attention to the strength of the leader.
A total of 17 financings, 11 financing of more than 100 million cancer early screening products for early detection and early warning of early cancer or precancerote lesions, early cancer screening and early diagnosis and treatment, remain the most effective way to reduce mortality.
in a broad sense, cancer early screening spans imaging, pathology and other disciplines, and the means of examination are diverse, including cytological examination, imaging examination, endoscopy, tissue biopsy, liquid biopsy, etc.
this paper only discusses cancer early screening based on genetic testing and liquid biopsy techniques.
Arterial Network statistics for the cancer early screening market between January 2020 and December 2020, a total of 16 enterprises with a clear layout of early screening business completed 17 financing, the cumulative amount of financing is about 6.3 billion yuan (calculation rules: exchange rate conversion according to 1 U.S. dollar - 6.57 yuan, tens of millions of yuan according to 10 million yuan, hundreds of millions of yuan, more than 100 million yuan).
2020 cancer early screening market financing data list (source: Arterial Orange) This year, a flood of capital poured into the cancer early screening track.
of the 16 enterprises that completed the financing, a total of 10 enterprises alone financing amounted to more than 100 million yuan, and some enterprises completed the financing of 100 million yuan in rounds A and B, which is a good example of the importance that capital attaches to this track.
Health completed two financings worth more than RMB 100 million in one year, becoming the "funding king" of the cancer early screening circuit in 2020.
the future, capital will gradually gather towards head companies.
in the 10 million yuan level, there are five, all concentrated in the early stages of financing.
from the financing round, the 2020 cancer early screening track to A-wheel and B-wheel-based, the industry still has a large room for growth.
has been listed enterprises are stone-burning medicine and Panshengzi, both enterprises are tumor precision medicine enterprises, the line of business covers early diagnosis of tumors, treatment, full cycle, cancer early screening has not yet become the company's core source of income.
recently, both companies have published their 2020Q3 quarterly reports.
third quarter of 2020, the company achieved sales revenue of 124 million yuan, up 19.4% YoY and 15.8% YoY, respectively.
central laboratory model (sample model) remains the main source of revenue for stone burning, accounting for 73% of revenue, with year-on-year and month-on-month growth of more than 20%.
Pansheng's sales revenue in the third quarter of 2020 increased by 37.6% YoY and 10.1% YoY to RMB110 million, respectively, and the company's business was divided into three major sectors, with IVD, LDT and research services accounting for 26.9%, 63.8% and 9.3%, respectively.
, the IVD segment grew the fastest year-on-year in Q3, with year-on-year and 65.9% year-on-year growth, respectively, mainly due to sales growth in TheGenetron S5 sequencer and TheUng 8 Assay.
, both stone-burning medicine and pan-births attach great importance to the advance of the cancer early screening program.
November, Stone-burning Medicine released the latest data on ELSA-seq, a DNA methylated cancer early screening technique.
in a study of early samples of six types of cancer (lung, colorectal, liver, ovarian, pancreatic, esophageal, and esophageal) ELSA-seq achieved about 98 percent specificity and 81 percent sensitivity.
, Stone also plans to launch a pan-cancer early screening product for screening for 9 cancers (increased stomach, liver and bile cancer, and head and neck cancer).
pan-born children focus on the layout of liver cancer early screening.
September, HCCscreen™ an early screening liquid biopsy product for hepatocellular carcinoma based on high-volume sequencing technology (NGS), was awarded a "breakthrough medical device" by the FDA.
data show that the sensitivity is stable at more than 93% when HCScreen is 98% specific.
also noteworthy is that in November, Nohui Health submitted a listing application to the Hong Kong Stock Exchange, the country is expected to be born with cancer early screening as the core source of income of the gene screening cancer early screening listed companies.
from the 16 enterprise layout of cancer species, bowel cancer early screening is still a popular investment track, a total of 9 layout of bowel cancer early screening enterprises to obtain financing.
, Kang Liming Bio, and The Far Gene, which have been rooted in the early screening market for bowelcancer for many years, have all received large amounts of financing this year.
, in September this year announced the official layout of the cancer early screening market of the Gikai gene, but also to bowel cancer as an entry point.
, Gika gene has also been favored by capital, completing nearly 400 million yuan C round of financing.
of cervical cancer, liver cancer and lung cancer are also higher.
, cervical cancer, liver cancer, lung cancer have three conditions: high incidence, high early cure rate, existing screening methods have certain defects.
therefore, the choice of large demand, can be clinical intervention, and can develop more advantages than existing means of cancer, such enterprises are more favored by the capital market, can quickly occupy a favorable position in the market.
addition, pan-cancer screening is also a hot topic of capital concern, this year a total of 7 layout of pan-cancer screening enterprises to obtain financing.
and single cancer screening is mainly for high-risk groups, pan-cancer screening is mainly aimed at healthy people, can achieve a variety of cancer simultaneous detection, in the still severe cancer prevention and treatment work, pan-cancer early screening and single-cancer early screening complement each other, are to reduce cancer morbidity and mortality.
gene testing cancer early screening registration certificate was born, compliance will become mainstream 2020, cancer early screening products ushered in a major breakthrough, the first genetic test cancer early screening registration certificate was born in China.
November, Nohui Health developed the bowel cancer early screening product Chang Weiqing officially obtained the State Drug Administration issued an innovative three types of medical device registration certificate, the realization of cancer genetic testing early screening field "first certificate."
Previously, the intended use of approved product approvals in the industry was "assisted diagnosis", which could not be used alone or as a basis for early diagnosis or diagnosis of cancer, but merely to provide supporting evidence for clinicians to diagnose patients with suspected bowel cancer symptoms and to play a diagnostic role.
Chang Weiqing is used for screening of high-risk groups aged 40-74 years, including those with a high risk of bowel cancer but no clinical symptoms, from which healthy people and individuals at risk of bowel cancer and progressive adenomas are found to have hidden cases.
Domestic approved cancer early screening products (data source: State Drug Administration official website) arterial network statistics, as of 2020, a total of 7 cancer early screening products to obtain three types of medical device registration certificate, respectively, from Borcheng, Kang Liming Biology, Nohui Health, Jin Baihui Bio, for real biology, perspective life 5 enterprises.
of the approved products are still bowel cancer screening products, and more types of cancer early screening products are expected to be approved in the future.
note that Boer Cheng's bowel cancer early screening products in 2015 was approved, is the earliest approved cancer-assisted diagnostic products.
April this year, its early detection of stomach cancer products, SiboWei also received NMPA approval.
it is known that the sensitivity of the detection of stomach cancer is 61.76 percent, specificity is 85.07 percent, the detection rate of early gastric cancer is 5-10 times higher than traditional tumor markers.
addition, there are many enterprises in the early screening of cancer products have also made a breakthrough this year.
August, and Rui Gene launched its first preCar-based liver cancer early screening product Rathnin, a product designed and developed entirely for clinical needs, not only 6 to 12 months ahead of the traditional gold standard to distinguish the weak molecular biological differences between cirrhosis and liver cancer population, but also to monitor the recurrence of liver cancer, to provide patients with accurate postoperative dynamic monitoring, effectively prolong survival.
also note that in recent years, cancer early screening companies have focused on large-scale forward-looking research.
July,Far Gene published large-scale clinical data on early screening of pan-cancer species in the international authoritative journal Nature Communications, showing that PanSeer®s tests were able to detect trace ctDNA methylation signals for five cancers up to four years before clinical diagnosis.
September, Nohui Health released key data results from a large-scale multi-center registered clinical trial (Clear-C) for early screening of cancer.
results show that the detection sensitivity of ® colorectal cancer in Changweiqing is 95.5% and the detection sensitivity of FIT is 69.8%.
Chang Weiqing ® helps to alert clinicians to the risk of colorectal cancer and improve patients' compliance with further colonoscopy.
November, Kang Liming Bio announced the launch of the "China's early screening program for colorectal cancer in the medical population - SDC2 gene methylation technology screening colorectal cancer application multi-center research."
foreshadows that Kang Liming Bio is about to put the application for an early screening certificate for bowel cancer on the agenda.
,000 people have been tested in a forward-looking study of 4,500 HBsAg Plus, multi-center liver cancer early screening products launched in 2019.
of 297 subjects showed that sensitivity, specificity, PPV and NPV were 92%, 93%, 35% and 99.6%, respectively.
plans to launch a second HCCscreen screening of 2,500 people in the first half of 2021 as a registered study to be approved in China in the future.
cancer early screening products forward-looking multi-center research queue large-scale, long follow-up time, high cost, cancer early screening enterprises cash reserves and financing capacity put forward a high demand.
In Grail's case, the company's research program includes at least a few thousand patients, and the STRIVE study group has reached 100,000 levels, requiring long follow-up to those patients, with articles showing that large-scale clinical trials require about $1 billion in funding and are costly.
but forward-looking, large-scale clinical research is the only way to obtain a registration certificate for cancer early screening products, I believe that the follow-up to cancer early screening products forward-looking clinical research enterprises will gradually increase.
also foreshadows that compliance is certainly the mainstream of cancer early screening products, enterprises should pay attention to product certification work.
2020, domestic enterprises in pan-cancer early screening products have also achieved remarkable results.
early screening of cancer is the business highlight of 2020 with Rui Gene, in addition to the liver cancer early screening mentioned above, and Rui Gene is also in the layout of pan-cancer species early screening.
at the 2020 CSCO Conference, and Rui Gene for the first time announced its multi-cancer early screening road map: in three to five years, and Rui Gene strive to deliver five to eight chinese high-risk high-risk cancer early screening research results, and industrialization.
The domestic part is layout of pan-cancer screening enterprises (data source: arterial orange) and a tube of blood screening for a variety of cancers, a single type of blood screening has no obvious advantages, pan-cancer screening is bound to be the future trend of blood screening.
but screening for multiple cancers requires large-scale database and analysis capabilities.
In addition, single cancer early screening is generally used fluorescent PCR method, this technical route is low cost, involving several bits or more than a dozen points of detection with PCR method is sufficient, but multi-cancer early screening needs to detect a wide range of genes, need multi-gene, multi-point large panel detection, so the cost is also higher.
Also, the relationship between cancer and genes is very complex, a single detection of multiple cancers, need to solve the problem of traceability, if you can not determine where the cancer occurred, even if the detection of cancer is meaningless, still need to be checked one by one.
So, although the attention of pan-cancer species early screening is now large, but due to technical difficulties, analytical ability, database, cost and other limitations, pan-cancer species development speed is slower than single cancer species early screening products, there is no pan-cancer early screening products approved, to LDT services to enter the market products are also less, but also need a certain amount of time to grow.
ctDNA is still the hot spot of the day, can multi-group science become the star of tomorrow? Tumor markers are a kind of bio-chemical substances that exist and grow in the body, which can reflect certain biological characteristics and are synthesized and secreted by tumor tissue cells.
Recently, the research of commonly used markers for early tumor screening, such as ctDNA, CTC, miRNA and exosomes, has made rapid progress, and can detect traces of cancer as early as possible and become the direction of the development of new tumor markers.
ctDNA is a fragment of DNA that is secreted into the bloodstream by tumor necrosis, apoptosis, or normal secretion, carrying information about cancer-related genetic mutations that can be detected when the tumor mutates at the molecular level, and early detection of cancer.
ctDNA is a hot spot in the field of early screening of cancer, and the development is more mature.
industry giant Grail is achieving early screening for multiple cancers by testing the amount of ctDNA in the blood.
ctDNA degrades quickly and in low levels, especially in the blood of patients with brain and kidney cancer